FCRL1 and B-cell chronic lymphocytic leukemia: The impact of Fc receptor like molecules (including FCRL1 and FCRL2) have been elucidated in CLL, which predicts the IGHV mutation status and clinical progression [43], and can act as potential immunotherapeutic targets [61, 62].